Stock Market Reviews

Read and share opinions on CRDF (Cardiff Oncology, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Cardiff Oncology: Q3 Earnings Snapshot
  Nov 6, 2025
• Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
  Nov 6, 2025
• Cardiff Oncology to Participate in Two Upcoming Investor Conferences
  Nov 4, 2025
• Cardiff Oncology to Participate in Three Upcoming Investor Conferences
  Aug 28, 2025
• Cardiff Oncology Insiders Land Bargain With Gains Of US$244k
  Jul 30, 2025
• Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates
  Jul 29, 2025
• Cardiff Oncology: Q2 Earnings Snapshot
  Jul 29, 2025
• Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
  Jul 29, 2025
• Cardiff Oncology to share CRDF-004 trial data on July 29
  Jun 19, 2025
• Cardiff selloff brings attractive entry point, says H.C. Wainwright
  Jun 19, 2025
• Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
  Jun 17, 2025
• Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025
  Jun 2, 2025
• Cardiff Oncology First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
  May 10, 2025
• Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
  May 8, 2025
• Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients
  Apr 23, 2025
• Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  Apr 15, 2025
• Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
  Apr 15, 2025